Ninghui Mao

发表

Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

A. Wyatt, M. Lacouture, E. Antonarakis, 2023, British journal of cancer.